• Our Services

    We offer best-in-class research and consulting services pertaining to the markets of all geographies. Our experienced team of business analysts and consultants has mastered fundamental and advanced market research in diverse industries.

  • Syndicated Research

    Syndicated research is the most cost-effective market research approach, which gives an analytical outlook of the competitive positioning, product positioning, and size estimation of the market at the micro level. Our off-the-shelf reports offer key market insights that industry stakeholders require to base their business strategy on. Our syndicated research services empower our clients to meet diverse market objectives.

  • Customized Research

    we also deliver customized research services to address specific needs of our clients. With a vast pool of adroit analysts who are proficient in market research, we take pride in tailoring our research services to meet our clients’ definite requirements and aid their business growth.

  • Consulting Services

    Businesses, today, need to adapt themselves to the changes that transpire in the market. Staying abreast of the market trends, therefore, becomes imperative for accomplishing business objectives.

  • Our Vision

    To be the most trusted partner in our clients' success endeavors

Showing posts with label Stages. Show all posts
Showing posts with label Stages. Show all posts

Akt/Protein Kinase B (PKB) Inhibitors - Analysis by Stages, Drug Class, Company Profile, & Discovery Stage Insights

Akt/Protein Kinase B (PKB) Inhibitors - Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments published by Pharma Proff Akt/PKB inhibitors therapeutics currently exhibits a proliferating pipeline with 23 therapeutic candidates. 

Akt plays a critical role in the regulation of cell’s apoptotic pathway and it is being studied extensively for targeting cancerous cells. Akt inhibitors are therapeutics that obstruct the Akt pathways or Akt enzyme, which play a key role in proliferation of solid tumors or cancer cells. Akt are composed of various AGC kinases present in the cells that have hydrophobic motif at the c-terminus of their catalytic core.

According to the research findings, majority of the drug candidates in the pipeline are being developed to be administered by the oral route. It has been observed that oral route of medications is convenient; available in delayed or rapid release formulation; provides improved patient’s compliance; less risk of systemic infections; and has inexpensive nature. Akt inhibitors through oral route of administration have shown positive results in the clinical studies.

Browse Detailed Report on “Akt/Protein Kinase B (PKB) Inhibitors - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments” at: www.pharmaproff.com/report/pkb-inhibitors-pipeline-analysis

The companies who are developing Akt/PKB inhibitors for the treatment of various chronic diseases have shown positive clinical results in the various phases of drug development. For instance, in June 2018, F. Hoffman-La Roche Ltd. announced the interim results of Phase II study (LOTUS) for the drug candidate, ipatasertib, that showed improvement in patients with triple negative breast cancer (TNBC) toward overall survival (OS). This result was presented in the 2018 ASCO Annual Meeting, held in the U.S. The Phase II LOTUS study showed an increase in OS up to 23.1 months (median) in interventional study, as compared to 18.4 months (median) in placebo study.
  
Some of the key players involved in the development of Akt/PKB inhibitors include F. Hoffman-La-Roche Ltd, Eli Lilly & Company, Merck & Co. Inc., Novartis AG, Denovo Biopharma LLC, Diffusion Pharmaceuticals Inc., Astex Pharmaceuticals, ArQule Inc., Cotinga Pharmaceuticals Inc., and Oneness Biotech Co. Ltd.

Share:

Profile

Popular Posts

APSense

Labels

Linkedin Profile

APSense

Business Network

Recent Posts

Research Pages